Guidelines are available for the management of CPS such as hereditary breast ovarian cancer syndrome (HBOC; BRCA 1 and BRCA 2 genes) [5–9] and Lynch syndrome (LS; MLH1, MSH2, MSH6, and PMS2 genes) [10–13]. This evidence concerns the gene MSH6 and Lynch syndrome.